Chenxing Du

9PUBLICATIONS
40CO-AUTHORS
Medical mycologyHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Neurology and neuromuscular diseasesMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|May 05, 2026
Late and Durable Minimal Residual Disease Response Predicts Favorable Outcomes in Newly Diagnosed Multiple Myeloma.

|Feb 27, 2026
Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).

Wenqiang Yan, Chenxing Du, Rui Lv

|May 30, 2025
Identification of a CAR-Derived Clone by NGS-Based MRD After Fully Human BCMA CAR T-Cell Therapy in Multiple Myeloma.

Wenqiang Yan, Jiao Chang, Chenxing Du

|Aug 02, 2024
Clinical implications of residual normal plasma cells within bone marrow across various disease stages in multiple myeloma.

Wenqiang Yan, Lihui Shi, Jingyu Xu

|Jun 20, 2024
Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing.

Jian Cui, Xiaoyun Li, Shuhui Deng

|Apr 12, 2024
Fluorescence in situ hybridization reveals the evolutionary biology of minor clone of gain/amp(1q) in multiple myeloma.

Jian Cui, Yuntong Liu, Rui Lv

Pageof 2

Frequent Collaborators

7 joint publications

Gang An

6 joint publications

Wenqiang Yan

5 joint publications

Dehui Zou

5 joint publications

Jingyu Xu